Endemic mycoses - Are we making progress in management?

Nathan C. Bahr, George R. Thompson

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewThe endemic fungi are a significant cause of morbidity and mortality in effected patients. The range of endemicity for these are expanding with infections observed outside of traditional locations. Enhanced diagnostic and treatment practices may significantly alter patient outcomes.Recent findingsRecently completed clinical trials have focused on an assessment of improving efficacy while minimizing patient toxicity. Practice changing trials have been completed in histoplasmosis showing the utility of a single up-front liposomal amphotericin B dose followed by standard itraconazole dosing. The recent evaluation of several antifungal options including isauvconazole in the treatment of coccidioidomycosis also show promise for additional therapeutic agents. A recently conducted trial has also shown the superiority of amphotericin B therapy over itraconazole in the treatment of talaromycosis.SummaryThe increased range of endemic mycoses coupled with the growing immunocompromised patient population mandates continued investigation of improved diagnostic and therapeutic options. Advances in these areas have led to more rapid diagnosis and more efficacious antifungal therapy.

Original languageEnglish (US)
Pages (from-to)436-442
Number of pages7
JournalCurrent Opinion in Infectious Diseases
Issue number6
StatePublished - Dec 1 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.


  • blastomycosis
  • coccidioidomycosis
  • histoplasmosis
  • sporotrichosis
  • talaromycosis


Dive into the research topics of 'Endemic mycoses - Are we making progress in management?'. Together they form a unique fingerprint.

Cite this